**A breakthrough breast cancer treatment launched in the UAE is delivering promising results, helping reduce the likelihood of disease progression and death by 56% while offering new hope for patients.**
UAE Introduces Pioneering Breast Cancer Therapy That Cuts Disease Progression and Death Risk by 56%.
Abu Dhabi has marked a significant achievement in cancer treatment by becoming the location of the world’s first real-world administration of a groundbreaking breast cancer therapy designed to address treatment resistance before the disease visibly worsens.
The milestone was reached at Burjeel Cancer Institute, where specialists treated a woman in her forties diagnosed with advanced breast cancer using Camizestrant, a next-generation targeted therapy. The decision to begin the new treatment came after doctors identified early biological signs indicating that the patient’s cancer was developing resistance to her existing medication, despite conventional scans showing no evidence of disease progression.
Medical experts involved in the case said the development highlights the growing role of precision medicine in oncology, where treatment decisions are increasingly guided by genetic and molecular changes rather than waiting for visible symptoms or imaging results to confirm disease advancement.
The case was conducted under the oversight of the Department of Health – Abu Dhabi (DoH), further reinforcing the emirate’s ambitions to become a regional and global centre for advanced healthcare, personalised medicine, and innovative cancer treatment.
The patient was diagnosed with hormone receptor-positive, HER2-negative metastatic breast cancer, one of the most frequently diagnosed forms of breast cancer worldwide. Patients with this subtype often respond well to hormone-based therapies during the early stages of treatment. However, over time, cancer cells can evolve and develop mechanisms that allow them to bypass the effects of these medications.
One of the major challenges facing oncologists is identifying exactly when this resistance begins to develop. Traditionally, doctors rely on imaging scans and clinical symptoms to determine whether a treatment is no longer working. By the time disease progression becomes visible through these methods, valuable treatment time may already have been lost.
In this case, physicians adopted a more advanced approach by using circulating tumour DNA (ctDNA) testing, a highly sensitive blood-based technology that can identify genetic alterations associated with cancer growth. Rather than waiting for tumours to enlarge or symptoms to worsen, the test allowed doctors to monitor molecular changes occurring within the patient’s cancer in real time.
The analysis revealed the presence of an ESR1 mutation, a genetic alteration known to play a major role in resistance to hormone therapy. This mutation enables cancer cells to continue growing even when treatments designed to block hormone signals remain in place.
According to cancer specialists, ESR1 mutations are relatively uncommon when patients are first diagnosed. Fewer than five per cent of individuals typically show this alteration at the time of diagnosis. However, the likelihood increases substantially after prolonged treatment with hormone-blocking therapies and CDK4/6 inhibitors, which are commonly used to manage advanced breast cancer.
Research indicates that approximately four out of every ten patients receiving these therapies may eventually develop ESR1 mutations during the course of treatment. Once these mutations emerge, the effectiveness of standard hormone-based treatments can begin to decline.
What makes the Abu Dhabi case particularly remarkable is the timing of the discovery. The mutation was identified long before traditional methods could detect any signs of disease progression.
Doctors explained that molecular testing allowed them to uncover evidence of treatment resistance months before it would likely have appeared on diagnostic imaging scans. Studies have shown that genetic changes linked to cancer progression can often be detected in blood samples up to six months before radiological evidence becomes visible.
This early warning period provides physicians with a valuable opportunity to intervene before the disease gains momentum. Instead of waiting for tumours to grow or spread further, clinicians can modify treatment strategies at an earlier stage when the chances of maintaining disease control may be significantly higher.
The introduction of Camizestrant in this setting represents a major shift in how cancer care can be delivered. Rather than reacting to progression after it occurs, the treatment approach focuses on anticipating changes within the cancer and acting proactively.
Experts say this model reflects the future direction of oncology, where personalised medicine uses genetic information and advanced diagnostics to tailor treatments to individual patients. By understanding the unique biological behaviour of a person’s cancer, doctors can make more informed decisions and potentially improve long-term outcomes.
The successful use of ctDNA monitoring also demonstrates the growing importance of liquid biopsy technologies in cancer management. Unlike traditional tissue biopsies, which often require invasive procedures, liquid biopsies can be performed through a simple blood sample. This makes it easier to monitor patients regularly and track changes in tumour biology over time.
Healthcare professionals believe that such technologies could transform cancer care by providing earlier insights into treatment effectiveness and disease evolution. Instead of relying solely on periodic scans, doctors may increasingly use blood-based monitoring to guide treatment decisions more dynamically.
The achievement has attracted attention because it showcases how advanced diagnostic tools and targeted therapies can work together to improve patient management. By identifying resistance mechanisms before clinical deterioration occurs, medical teams gain additional opportunities to adjust therapies and potentially extend disease control.
Officials say the case also reflects Abu Dhabi’s continued investment in cutting-edge healthcare technologies. The emirate has increasingly focused on supporting innovation in medical research, genomics, and precision medicine as part of broader efforts to enhance healthcare outcomes.
Through collaborations between healthcare institutions, researchers, and regulatory authorities, Abu Dhabi is positioning itself at the forefront of medical innovation in the region.
The treatment milestone demonstrates how emerging technologies are reshaping the cancer care landscape. Precision oncology is moving beyond traditional approaches and embracing methods that analyse the genetic characteristics of cancer to guide treatment choices.
Experts believe that early detection of resistance mutations could become a standard part of care for many cancer patients in the future. By identifying biological changes before they result in visible disease progression, clinicians may be able to preserve treatment effectiveness for longer periods and improve patient quality of life.
For the patient involved, the early detection of the ESR1 mutation allowed doctors to take action at a critical moment. Rather than waiting for evidence of worsening disease to appear on scans, the medical team was able to transition to a therapy specifically designed to address the newly identified resistance mechanism.
The case serves as an example of how advances in genetic testing and targeted medicine are changing expectations for cancer treatment. As technology continues to evolve, healthcare providers may gain increasing ability to anticipate disease behaviour and personalise therapies based on each patient’s unique molecular profile.
Medical experts say this approach represents a significant step toward more proactive, data-driven cancer care, where treatment decisions are guided by real-time biological insights rather than delayed signs of progression.
The achievement not only marks a global first for the administration of Camizestrant in a clinical setting but also highlights the growing role of Abu Dhabi in advancing innovative healthcare solutions that could influence cancer treatment practices worldwide.
The early identification of genetic changes associated with treatment resistance gave doctors a valuable opportunity to modify the patient’s therapy before the cancer showed any visible signs of worsening.
After detecting the ESR1 mutation through advanced blood-based monitoring, the medical team decided to transition the patient to Camizestrant, an innovative oral therapy specifically developed to address both standard and mutated forms of the estrogen receptor. The treatment is designed to overcome one of the major challenges in hormone receptor-positive breast cancer, where genetic alterations can allow tumour cells to bypass conventional hormone-blocking therapies and continue growing.
By acting at the molecular stage rather than waiting for physical evidence of disease progression, doctors were able to intervene earlier than would typically be possible using traditional monitoring methods. This proactive approach reflects a broader shift in cancer care toward personalised medicine, where treatment decisions are increasingly guided by genetic and biological insights.
According to specialists involved in the case, the patient has responded well to the treatment strategy and remains clinically stable. Her condition continues to be carefully monitored by a multidisciplinary team that includes oncologists, genetic specialists, radiologists, pathologists, and other healthcare professionals working together to assess her progress and adjust care when necessary.
Medical experts say the involvement of a multidisciplinary team is a key component of modern cancer treatment. By bringing together specialists from different fields, healthcare providers can evaluate complex cases from multiple perspectives and develop more comprehensive treatment plans tailored to individual patients.
The patient’s ongoing stability is being viewed as an encouraging sign and highlights the potential value of detecting treatment resistance before conventional imaging reveals changes in tumour activity.
Health officials in Abu Dhabi have described the achievement as an important example of how emerging technologies can transform patient care. The case demonstrates how advances in molecular diagnostics, genetic testing, and precision medicine can provide healthcare professionals with earlier and more detailed information about disease behaviour.
Dr. Noura Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said the future of healthcare increasingly depends on the ability to identify risks and biological changes before they develop into more serious medical problems.
She explained that healthcare systems around the world are moving away from models focused solely on treating advanced disease and are instead embracing strategies centred on prevention, prediction, and early intervention. The goal is to identify warning signs sooner, allowing doctors to take action before conditions worsen and become more difficult to manage.
According to Dr. Al Ghaithi, the successful administration of Camizestrant in a clinical setting demonstrates Abu Dhabi’s commitment to advancing these principles through investment in innovative healthcare technologies and personalised treatment approaches.
She noted that the emirate has been working to build a healthcare ecosystem that prioritises early diagnosis, precision medicine, and patient-centred care. By integrating advanced diagnostic tools into routine clinical practice, healthcare providers can make more informed decisions and potentially improve outcomes for patients facing complex diseases such as cancer.
The ability to introduce a next-generation treatment based on molecular findings rather than visible disease progression reflects a new era in oncology, where healthcare professionals can intervene earlier and with greater precision than ever before.
Officials say this approach aligns with Abu Dhabi’s broader healthcare strategy, which focuses on leveraging innovation, research, and technology to enhance the quality of medical services and strengthen patient outcomes.
The case also highlights the growing role of precision medicine in cancer treatment. Precision medicine involves tailoring healthcare decisions to the unique characteristics of each patient, including their genetic profile, disease biology, and individual response to treatment.
Rather than applying a one-size-fits-all approach, precision oncology seeks to identify the specific molecular drivers of a patient’s cancer and select therapies that target those mechanisms directly. This can lead to more effective treatment strategies and reduce the likelihood of unnecessary side effects.
Prof. Humaid Al Shamsi, Chief Executive Officer of Burjeel Cancer Institute, said the achievement extends far beyond the introduction of a new medication. In his view, the true significance lies in the ability to identify treatment resistance before traditional clinical methods would normally detect it.
He explained that for many years, oncologists have relied heavily on imaging scans and clinical symptoms to determine whether a patient’s cancer is responding to treatment. While these tools remain essential, they often reveal disease progression only after important biological changes have already taken place.
The introduction of advanced molecular monitoring allows doctors to gain insights into the cancer’s behaviour at a much earlier stage. By identifying genetic mutations associated with resistance, clinicians can adjust treatment plans before the disease begins to progress visibly.
Prof. Al Shamsi described this capability as a major advancement in cancer care because it enables doctors to move from a reactive approach to a proactive one. Instead of waiting for tumours to grow or symptoms to appear, medical teams can respond to early warning signals and potentially prevent further disease development.
He noted that this shift has the potential to improve patient outcomes by preserving treatment effectiveness for longer periods and reducing the risk of uncontrolled disease progression.
The case also demonstrates the practical value of liquid biopsy technologies, which analyse circulating tumour DNA found in blood samples. Unlike traditional tissue biopsies, liquid biopsies can be performed more easily and repeatedly, allowing doctors to monitor cancer evolution over time with minimal discomfort to patients.
Experts believe that widespread adoption of such technologies could significantly change how cancer patients are monitored and treated in the future. Regular molecular testing may help physicians identify emerging resistance mechanisms, evaluate treatment effectiveness, and personalise therapies based on real-time biological information.
The successful use of Camizestrant following the detection of an ESR1 mutation serves as a powerful example of how these innovations can work together. Advanced diagnostics identified the problem early, while targeted treatment provided an opportunity to address it before clinical deterioration occurred.
Healthcare leaders say the milestone reinforces Abu Dhabi’s position as a centre for medical innovation and advanced cancer care. Through continued investment in research, technology, and precision medicine, the emirate is helping shape new approaches to disease management that may influence healthcare practices well beyond the region.
As cancer treatment continues to evolve, experts expect molecular monitoring and personalised therapies to play an increasingly important role. The ability to anticipate disease changes before they become clinically apparent represents a significant step forward in oncology and offers new hope for improving long-term patient outcomes.
For the medical team involved, the case is not simply about using a new drug—it is about demonstrating a new way of thinking about cancer care. By combining early detection, genetic analysis, and targeted intervention, healthcare providers can make treatment decisions earlier, more accurately, and with greater confidence.
This achievement marks another important milestone in the ongoing transformation of cancer medicine, where science and technology are enabling doctors to stay one step ahead of disease progression and deliver more personalised care to patients.
Prof. Al Shamsi further explained that ongoing molecular surveillance is transforming the way oncologists manage cancer treatment. By regularly analysing genetic changes within a patient’s tumour, physicians can gain a deeper understanding of how the disease is evolving and whether current therapies remain effective.
He noted that cancer is not a static condition. As treatment progresses, tumour cells can develop new mutations that alter their behaviour and affect how they respond to medication. Continuous monitoring allows healthcare teams to identify these biological changes early and adjust treatment strategies accordingly.
According to Prof. Al Shamsi, this approach represents a major step toward truly personalised cancer care. Rather than relying solely on standard treatment protocols, doctors can make decisions based on the unique genetic profile of each patient’s disease. This enables therapies to be tailored more precisely to individual needs, potentially improving outcomes while reducing the risk of ineffective treatment.
He said that advances in molecular diagnostics are giving clinicians access to valuable information that was previously unavailable in routine practice. By tracking tumour DNA through simple blood tests, doctors can monitor cancer activity in real time and detect warning signs long before traditional imaging methods reveal any changes.
The ability to observe these molecular developments provides a more dynamic view of the disease. Instead of waiting for tumours to grow or symptoms to appear, healthcare teams can respond to subtle biological signals that indicate resistance may be emerging. This proactive approach can help maintain disease control and improve long-term management strategies.
The treatment strategy adopted in Abu Dhabi is supported by evidence from the international SERENA-6 clinical trial, a major study that investigated the effectiveness of Camizestrant in patients whose cancers had developed specific genetic alterations linked to hormone therapy resistance.
Researchers involved in the trial sought to determine whether intervening at the molecular stage—before visible disease progression occurred—could lead to better patient outcomes. The results provided strong evidence in favour of this approach.
According to findings from the study, patients who were switched to Camizestrant after the detection of ESR1 mutations experienced significantly better outcomes compared with those who continued receiving conventional hormone-based treatment.
Data from the trial demonstrated that moving eligible patients to the next-generation therapy reduced the likelihood of disease progression or death by 56 per cent. Medical experts described this as a substantial improvement, highlighting the potential value of early intervention guided by molecular testing.
The results suggest that identifying treatment resistance before it becomes clinically apparent can have a meaningful impact on patient outcomes. By acting earlier, doctors may be able to delay disease progression and preserve treatment effectiveness for longer periods.
Researchers said the findings reinforce the importance of incorporating advanced monitoring tools into routine cancer care. Detecting resistance mutations at an early stage gives healthcare professionals an opportunity to adapt treatment plans before the disease gains momentum.
The study also revealed notable differences in how long patients were able to maintain disease control. Individuals who received Camizestrant experienced significantly longer periods without disease progression compared with those who remained on conventional hormone therapy.
Patients treated with the newer medication achieved disease control for a median duration of approximately 16 months. In comparison, those who continued with traditional treatment approaches experienced disease control for around 9.2 months.
This improvement represents several additional months during which the disease remained stable, an outcome that can have a meaningful effect on both quality of life and overall treatment planning.
Cancer specialists say extending the period of disease control is one of the primary objectives in the treatment of advanced breast cancer. Longer stability often allows patients to maintain daily activities, avoid more aggressive treatments for extended periods, and experience improved overall wellbeing.
The SERENA-6 findings have attracted considerable attention within the oncology community because they demonstrate how combining molecular monitoring with targeted treatment can produce measurable clinical benefits.
Experts believe the study provides further evidence that the future of cancer care will increasingly rely on precision medicine approaches. Instead of waiting for visible progression, doctors may use genetic information to guide earlier and more strategic interventions.
Healthcare leaders in the UAE view the successful use of Camizestrant as part of a broader transformation taking place across the country’s medical sector. Significant investments in advanced diagnostics, genomic medicine, and specialised cancer programmes are helping bring cutting-edge treatments closer to patients.
Historically, many individuals seeking access to the newest cancer therapies often had to travel internationally to participate in clinical trials or receive specialised treatment unavailable in their home countries. Such journeys could involve substantial financial costs, logistical challenges, and emotional stress for both patients and their families.
Medical professionals say the latest milestone demonstrates that patients in the UAE are increasingly gaining access to innovative therapies without needing to leave the country. As healthcare capabilities continue to expand, more advanced treatment options are becoming available within local medical institutions.
This development is particularly important for cancer patients, who often benefit from receiving care close to their support networks and families. Access to world-class treatments locally can improve convenience while reducing the burden associated with overseas travel.
Healthcare experts believe the introduction of next-generation therapies such as Camizestrant reflects the growing maturity of the UAE’s healthcare ecosystem. The country has invested heavily in attracting medical expertise, building specialised treatment centres, and adopting advanced technologies that support precision medicine.
As a result, patients are increasingly able to receive sophisticated care that meets international standards without needing to seek treatment abroad.
The achievement also highlights the role of collaboration between healthcare providers, researchers, regulatory authorities, and technology innovators. Such partnerships help accelerate the adoption of new therapies and ensure that promising medical advances reach patients more quickly.
Experts say the combination of molecular monitoring, targeted therapies, and personalised treatment planning is reshaping expectations for cancer care worldwide. The ability to identify resistance early and intervene before visible disease progression occurs represents a significant advancement in oncology.
For patients, these developments offer new hope that treatment can be adapted more effectively as their disease changes over time. For doctors, they provide additional tools to make informed decisions based on real-time biological information rather than waiting for traditional indicators of progression.
As precision medicine continues to evolve, healthcare professionals expect similar approaches to be applied across a growing range of cancers and other complex diseases. The ultimate goal is to deliver more personalised, proactive, and effective care tailored to each patient’s unique condition.
The Abu Dhabi milestone demonstrates how these innovations are already beginning to move from research settings into everyday clinical practice. By combining advanced diagnostics with next-generation therapies, healthcare teams are creating new opportunities to improve outcomes and enhance the quality of care available to patients across the UAE and beyond.
